US Pharma MarketingThe post CereVasc raises $85m to advance hydrocephalus treatment appeared first on Medical Device Network.
CereVasc raises $85m to advance hydrocephalus treatment
CereVasc’s eShunt is an implantable system designed to treat normal pressure hydrocephalus by draining excess cerebrospinal fluid. CereVasc’s eShunt is an implantable system designed to treat normal pressure hydrocephalus by draining excess cerebrospinal fluid. The Hydrocephalus Association estimates that 800,000 Americans may be living with NPH. Crdit: SkazovD / Shutterstock.com CereVasc has raised $85m, providing the clinical stage company with a cash runway to support the ongoing development of its eShunt system for normal pressure hydrocephalus (NPH) treatment. The Massachusetts-based company’s Series C financing round was led by Piper Sandler Merchant Banking and featured participation from Johnson & Johnson Innovation…
CereVasc’s eShunt is an implantable system designed to treat normal pressure hydrocephalus by draining excess cerebrospinal fluid.
Source: Medical Device Network